ArticleScientific reports2025
Estimating the impact of pill burden on health utilities in hemodialysis therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Finding the sweet spot in green nephrology: the intersection of environmental sustainability and excellence in patient care.Clinical kidney journal · 2026Review
- Association Between Pain Self-Efficacy and Adherence to Hemodialysis Regimen.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients undergoing hemodialysis often require numerous medications because of comorbidities including hyperphosphatemia, diabetes, and anemia, coupled with water restrictions. Reducing pill burden may alleviate psychological stress and improve quality of life (QOL). However, standardized instruments such as the EuroQOL 5 Dimensions inadequately measure these effects. We investigated the impact of pill burden on utility scores using a vignette-based time trade-off (TTO) method. Members of the general population were interviewed in person using vignettes representing seven health states with varying daily pill burdens (2, 3, 6, 9, 12, 24, and 36 tablets) in the context of hemodialysis patients, including disease characteristics, symptoms, and daily life restriction. Utility scores were evaluated using the TTO method and the impact of pill burden on QOL was estimated. The mean age (44.5 years) and sex distribution (50.5% male) of the 107 participants closely matched the general population of Japan. Utility scores decreased with higher pill burdens, ranging from 0.373 (0.579) [mean (standard deviation)] for 2 tablets/day to 0.239 (0.568) for 36 tablets/day. Compared with 2 tablets/day, the utility score for 6 tablets/day was significantly lower [mean (standard deviation) difference: 0.046 (0.223), P = 0.034, paired t-test)], with the difference showing a more significant as the number of tablets increased. Subgroup analyses by sex and age showed consistent trends with no significant differences between groups. A higher pill burden was associated with lower utility scores, highlighting its negative impact on QOL in patients undergoing hemodialysis. Reducing pill burden may improve QOL and address challenges related to water restrictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.